DarioHealth Corp DRIO.OQ DRIO.O is expected to show a rise in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
The New York City-based company is expected to report a 10.4% increase in revenue to $6.906 million from $6.26 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for DarioHealth Corp is for a loss of 23 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for DarioHealth Corp is $2.25, about 75.6% above its last closing price of $0.55
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.12
-0.12
-0.14
Missed
-20
Dec. 31 2025
-0.34
-0.33
-0.09
Beat
73
Sep. 30 2024
-0.28
-0.27
-0.25
Beat
8.5
Jun. 30 2024
-0.55
-0.55
-0.08
Beat
85.6
Mar. 31 2024
-0.48
-0.40
-0.20
Beat
50.6
Dec. 31 2023
-0.54
-0.55
-0.50
Beat
9.6
Sep. 30 2023
-0.48
-0.46
-0.49
Missed
-6.5
Jun. 30 2023
-0.57
-0.52
-0.58
Missed
-11.1
This summary was machine generated August 4 at 13:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)